Guangzhou Cellprotek Pharmaceutical Co., Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 3 name spellings.
0
Ending by 2030
Jul 2031
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 23, 2027The maintenance fee for NEURO-PROTECTIVE AGENTS AND USES THEREOF (As Amended) (US 10,357,500) comes due Jan 23, 2027. Unpaid by Jul 23, 2027, it lapses early.
- 1 fee due Apr 20, 2027The maintenance fee for 5α-androstane (alkyl)-3β, 5, 6β-triol injection and preparation method therefor (US 9,161,985) comes due Apr 20, 2027. Unpaid by Oct 20, 2027, it lapses early.
- 2 fees due Aug 23 to 27, 2027 · next Aug 23
- 1 fee due Oct 26, 2027The maintenance fee for Use of 5α-androstane-3β,5,6β-triol in preparation of neuroprotective drugs (US 9,320,743) comes due Oct 26, 2027. Unpaid by Apr 26, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,809,309 | Use of 5α-androstane (alkyl)-3β,5,6β-triol in preparation of neuroprotective drugs In force · From the USPTO record | In force | From the USPTO record | |
| US 9,265,837 | 5α-androstane-3β,5,6β-triol injection and preparation method therefor In force · From the USPTO record | In force | From the USPTO record | |
| US 9,161,985 | 5α-androstane (alkyl)-3β, 5, 6β-triol injection and preparation method therefor In force · From the USPTO record | In force | From the USPTO record | |
| US 9,320,743 | Use of 5α-androstane-3β,5,6β-triol in preparation of neuroprotective drugs In force · From the USPTO record | In force | From the USPTO record | |
| US 9,688,716 | Crystalline forms of 5α-androstane-3β,5,6β-triol and preparation methods therefor In force · From the USPTO record | In force | From the USPTO record | |
| US 9,944,672 | Crystalline forms of 5α-androstane-3β,5,6β-triol and preparation methods therefor In force · From the USPTO record | In force | From the USPTO record | |
| US 9,944,673 | Crystalline forms of 5α-androstane-3β,5,6β-triol and preparation methods therefor In force · From the USPTO record | In force | From the USPTO record | |
| US 10,357,500 | NEURO-PROTECTIVE AGENTS AND USES THEREOF (As Amended) In force · High confidence | In force | High confidence | |
| US 10,835,539 | Neuro-Protective Agents and Uses Thereof In force · High confidence | In force | High confidence | |
| US 11,584,802 | Hexokinase 2-Specific Inhibitors for Use in Acute Central Nervous System Injury In force · High confidence | In force | High confidence |
Also on record, not counted in the 14: 1 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
Every application published under this name has become a patent.